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Abstract
Parkinson’s disease is the second most common neurodegenerative disorder without effective 
treatment. It is generally sporadic with unknown etiology. However, genetic studies of rare familial 
forms have led to the identification of mutations in several genes, which are linked to typical 
Parkinson’s disease or parkinsonian disorders. The pathogenesis of Parkinson’s disease remain 
largely elusive. Here, we report a novel genetic locus for an autosomal dominant, clinically typical 
and Lewy body confirmed Parkinson’s disease on the short arm of chromosome 20 (20pter-p12) 
and TMEM230 as the disease-causing gene. We show that TMEM230 encodes a transmembrane 
protein of secretory/recycling vesicles, including synaptic vesicles in neurons. The disease-linked 
TMEM230 mutants impair synaptic vesicle trafficking. Our data provide the first genetic evidence 
that a mutant transmembrane protein of synaptic vesicles in neurons is etiologically linked to 
Parkinson’s disease, with novel implications in understanding the pathogenic mechanism of 
Parkinson’s disease and for developing rational therapies.
Parkinson’s disease (PD) is a neurodegenerative disorder affecting approximately 1% of the 
population over age 60, with a lifetime incidence of over 2%. PD is characterized clinically 
by resting tremor, bradykinesia, rigidity, postural instability and a variety of other motor and 
non-motor symptoms, and pathologically by the loss of dopamine-producing neurons in the 
substantia nigra pars compacta in association with the presence of Lewy bodies in some 
surviving neurons1. Most of PD cases are sporadic with unknown etiology. Rare PD families 
have provided unique resources for identification of PD-linked genetic defects, and for the 
development of cellular and animal models for a better understanding of its pathogenesis2,3. 
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Since the identification of α-synuclein gene (SNCA) as the first PD-linked gene4, several 
other causative or risk genes for PD or other parkinsonian disorders have been 
discovered5-22. Among the disease-causing genes, mutations in SNCA and LRRK2, or an 
increase in SNCA copy number are linked to Lewy body confirmed PD. A perspective on 
this topic was comprehensively reviewed by Langston et al1,23. However, despite extensive 
ongoing studies of the previously identified molecule targets, the pathogenic mechanisms of 
PD remain largely elusive1,24. Here, we show that mutations in TMEM230 lead to clinically 
typical and Lewy body confirmed PD. Our findings suggest synaptic vesicle trafficking 
defects underlie PD pathogenesis, with implications in therapeutic development.
RESULTS
A novel locus of dominant and Lewy body confirmed PD on 20p
We have followed and studied a large North American PD family (#9853) of Northern 
European ancestry for over two decades. This family included 81 members, among whom 15 
were affected (Supplementary Fig. 1). Detailed clinical information was obtained from 14 
affected individuals, who exhibited variable symptoms of typical PD, including 
bradykinesia, resting tremor, rigidity, and postural instability. The symptoms responded well 
to levodopa therapy in most cases. The mean age at the disease onset was 67.0 ± 9.5 (SD) 
years (range: 48-85). Death occurred after an average of 13.2 ± 4.1 (SD) years. Pathological 
analysis of autopsy samples from three affected individuals (II-4, II6 and II-14) showed PD 
pathology, including marked loss of dopaminergic neurons and the presence of typical Lewy 
bodies and Lewy neurites in the substantia nigra pars compacta.
We have collected DNA samples from 65 members, including 13 affected individuals from 
this family (Supplementary Fig. 1). We performed genome-wide linkage analysis using over 
300 microsatellite polymorphic markers, and subsequently a dense panel of 21 microsatellite 
markers on the 20p. Two-point LOD score over 3.3 and multi-point score over 3.8 were 
obtained for several informative markers on the tip of chromosome 20 (Supplementary Table 
1). We constructed a genetic haplotype that was shared by all the 13 affected members, but 
not by the two older unaffected individuals (II-9 and II-12) in the second generation 
(Supplementary Figs. 1 and 2). The individual II-9 died at the age of 87 years without any 
signs of PD. The individual II-12 died at age of 78 years without PD symptoms and there 
was no PD pathology at autopsy. Both unaffected members in the second generation did not 
carry the disease-linked haplotype. A crossover between D20S901 and D20S894 observed in 
affected individuals II-1 and III-1 defined the lower border of the shared haplotype 
(Supplementary Fig. 1), thus, establishing a novel locus for this autosomal dominant, 
clinically typical and Lewy body confirmed PD in a minimum candidate region (MCR) of 
10.7Mb in 20pter-p12, above D20S894 on the short arm of chromosome 20.
Mutations in TMEM230 in PD
There are a total of 141 known genes in this MCR. We initially analyzed exons of 17 
protein-coding genes in one affected individual (II-11) by Sanger sequencing, but we did not 
find any novel variants (Supplementary Table 2). We then employed a whole-exome 
sequencing approach. We selected one unaffected individual (II-9), who lived to 87 years old 
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without PD, and four distantly related affected individuals (II-4, III-1, III-20 and III-26), so 
that the number of the co-segregating, but non-PD-linked variants could be reduced.
Across the five individuals, we identified a total of 90,289 variants. We excluded the variants 
with an average heterozygosity of >0.01 in multiple databases, including the dbSNP (v130), 
HapMap and 1000 Genome databases. After filtering for functional significance (i.e., 
nonsense, missense, splice site) and removing the tolerated variants, a single missense 
variant (c.422G>T, and p.Arg141Leu encoded by TMEM230) was left. This variant was 
present in four PD patients, but not in the unaffected individual. We performed Sanger 
sequencing and co-segregation analysis using all additional samples available to us from this 
family. The Arg141Leu mutation fully co-segregated with the disease in this large kindred 
(Supplementary Figs. 1 and 3a). All 13 affected individuals whose DNA samples were 
available for sequencing analysis carried this mutation. This mutation was also presumably 
present in the other two affected deceased individuals (I-1 and II-8), due to transmission of 
this mutation to their next generations. This mutation was not present in any SNP databases 
with a total of 15,184 sequenced alleles (Supplementary Table 4). We further sequenced a 
control cohort of 1,238 samples from North America, and we did not find this mutation 
(Supplementary Table 4). Consistent with our linkage data, TMEM230 is located on 20p13, 
about 5.1Mb from 20pter, in the middle of our mapped 10.7Mb-MCR.
In addition to the TMEM230-Arg141Leu mutation, two other novel variants were identified 
on the affected chromosome in our unfiltered exome sequencing data. These two variants 
were also located in the MCR, but in the intronic regions without apparent functional 
significance (Supplementary Table 5). To make sure that all the exons in the MCR were fully 
and sufficiently covered, we further Sanger-sequenced all the 10 exons that had a relatively 
lower coverage of ≤ 20X (2-20X) in our exome sequencing data. We did not find any new 
variants in the MCR on the affected chromosome. Thus, the TMEM230-Arg141Leu 
mutation appeared to be the only missense mutation shared by all the patients in this large 
PD family in this MCR.
To examine whether TMEM230 mutations are present in other PD patients, we analyzed 832 
PD DNA samples collected from North America, including 433 familial PD and 399 
sporadic PD cases. We found two novel mutations in TMEM230. A c.551A>G was 
identified in a familial PD patient. This mutation changes the stop codon (X) to a Trp 
(X184Trp), adding six amino acids (WHPPHS) at the C-terminal (Supplementary Fig. 3b). 
This male patient had a disease onset at the age of 33 years. His maternal male cousin was 
described to have PD, with the disease onset at the age of 35 years. No additional 
information and DNA samples from this family were available for further analysis. The 
other mutation, c.275A>G (p.Tyr92Cys), was identified in a sporadic male PD patient with 
the disease onset at age 34 years (Supplementary Fig. 3c). His mother carries this mutation 
without PD signs when evaluated at 57 years old. Similarly, the X184Trp and Tyr92Cys 
mutations were not present in SNP databases with a total of 15,184 alleles sequenced and in 
over 1,000 in-house controls (Supplementary Table 4). The X184Trp and Tyr92Cys were 
identified in a single patient each, their pathogenicity to PD remains to be further examined. 
Through our screening, we also found three other missense variants, which are known SNPs, 
in both PD and control cohorts with similar frequencies (Supplementary Table 4), and 
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obviously these known SNPs did not co-segregate with PD in respective families 
(Supplementary Fig. 4).
To test if mutations in TMEM230 cause PD in other ethnic PD patients, we extended our 
genetic study to a Chinese PD cohort of 574 cases, including 225 familial index cases and 
349 sporadic cases. We identified a single mutation, c.550_552delTAGinsCCCGGG, in 
seven familial index cases from seven unrelated families, but not in the sporadic cases 
(Supplementary Fig. 3d and Supplementary Figs. 5-11). In this mutation, the stop codon 
TAG is replaced by six nucleotides CCCGGG, resulting in the replacement of the stop codon 
(X) by proline and glycine (p.X184ProGly) at the protein level, adding seven amino acids 
(PGHPPHS) at the C-terminal (Supplementary Fig. 3d). Notably, the last five amino acids 
(HPPHS) are identical in both X184Trp and X184ProGly mutants (Fig. 1a). In two families 
with additional DNA samples available from other PD patients, we could confirm the co-
segregation of disease with this mutation (Supplementary Figs. 8 and 11). In these nine PD 
patients from seven families with the X184ProGly mutation, five patients from four families 
are homozygotes (Supplementary Fig. 1d and Supplementary Figs. 5, 6, 9 and 11). To test if 
mutations in other known PD-linked genes, such as SNCA, LRRK2 and VPS35, or other 
parkinsonism-linked genes, are present in these Chinese PD patients, we further performed 
whole-exome sequencing using the DNA samples from these nine Chinese PD patients with 
the X184ProGly mutation. We did not find new variants in these genes. We Sanger-
sequenced DNA samples from our 528 in-house Chinese controls, and we did not find this 
mutations. Moreover, this mutation was not present in the Chinese exome-sequencing 
database, including 9,906 neurologically normal Chinese controls, from the BGI (Beijing 
Genomics Institute)-Shenzhen. Notably, neither of the four TMEM230 mutations identified 
in PD patients in this study, including Arg141Leu, Tyr92Cys, X184Trp and X184ProGly, 
was present in the Exome Aggregation Consortium database from a total of 60,706 unrelated 
individuals.
The apparent aggregation of the X184ProGly homozygotes in the Chinese familial PD 
cohort may suggest an increased penetrance of this homozygous mutation in the late-onset 
PD due to a dose effect. The obligate heterozygous carrier of a homozygous patient had not 
developed PD before she died at 96 years old (Supplementary Fig. 6), which may suggest an 
incomplete penetrance of this mutation in heterozygous condition in some mutation carriers.
To test whether the high prevalence of the X184ProGly mutation in the Chinese PD patients 
is due to a founder effect, we analyzed three TMEM230 intragenic SNPs closely flanking 
the mutation site in five homozygous patients (Supplementary Fig. 12). The presence of 
heterogeneity for these SNPs in four out of these five homozygous patients suggests that the 
X184ProGly arise from independent mutation events, or a very ancient mutation 
(Supplementary Fig. 12). The X184Trp and X184ProGly were identified in different ethnic 
populations, but both mutations occur at the stop codon, suggesting a hotspot for the PD-
linked mutations. The X184ProGly mutation accounts for 7/225 (3.1%) of Chinese familial 
PD index cases in our cohort, appearing to be the most prevalent single genetic defect in the 
Chinese familial PD cases. Notably, the amino acids or codon at Arg141, Tyr92 and X184 
are highly evolutionally conserved (Fig. 1a).
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TMEM230 in synaptic vesicles in neurons
TMEM230, also known as C20orf30, is a gene yet to be experimentally characterized. There 
is no apparent sequence homology to any other known genes or proteins. There are four 
major alternatively spliced mRNA variants from five exons in humans (Supplementary Fig. 
13a). The mRNA variant 1 encodes protein isoform 1, a polypeptide of 183 amino acids. 
The other three mRNA variants (2-4) encode protein isoform 2, a polypeptide of 120 amino 
acids (Supplementary Fig. 13a). Isoform 2 lacks the N-terminal 63 amino acids of the 
isoform 1 in humans. Across species spanning zebra fish to most mammals, there is only a 
single protein isoform of 120 amino acids that is equivalent to human isoform 2. The longer 
isoform 1 appears to be present only in primates. The N-terminal polypeptides of isoform 1 
in the primates are divergent in size and homology. However, the C-terminal polypeptides of 
120 amino acids, which are identical to isoform 2, are highly conserved, suggesting the 
functional importance of isoform 2.
We characterized the transcriptional and translational profiles of human TMEM230. Our 
data suggest that isoform 2 accounts for >95% of the total protein isoforms (Supplementary 
Fig. 13).
TMEM230 encodes a transmembrane protein (TMEM230) of unknown location and 
function. Computer programs for protein structure and function prediction suggested that 
this protein has two major α-helical domains (Fig. 1b) and two transmembrane segments, 
with the N- and the C-terminal regions exposed to the cytosol25-27 (Fig. 1c). Notably, all 
four PD-associated mutations are located in the loop regions (Fig. 1c). The Tyr92Cys, 
X184Trp and X184ProGly were not predicted to remarkably alter the structure. However, 
the positively charged amino acid residual Arg141 in TMEM230-Wt was predicted to be 
located on the luminal site, adjacent to the second transmembrane segment. When the 
Arg141 is mutated to Leu141, the Leu141 appeared to be a part of the second 
transmembrane segment and buried in the membrane.
To examine the subcellular localization of TMEM230 protein, we performed 
immunohistochemical staining of mouse brain sections. TMEM230 appeared to localize to 
vesicle structures in neurons, including dopaminergic neurons in the substantia nigra 
(Supplementary Fig. 14). To characterize these structures, we engineered 25 TMEM230 
constructs in three expression vectors and performed confocal microscopy using transiently 
transfected SH-SY5Y and Neuro-2a cells. TMEM230 showed a similar pattern of 
membrane-bound distribution in both cell types, but Neuro-2a cells revealed better 
morphological details due to their relatively larger size (Supplementary Fig. 15). Therefore, 
we used Neuro-2a cells for further characterization. We observed that the vesicle structures 
labeled by TMEM230 were predominantly located in the perinuclear region as clusters and 
in other cytosolic areas as isolated vesicles or vesicle clusters (Supplementary Fig. 15a-o). 
Both isoforms 1 and 2 showed a similar pattern of distribution (Supplementary Fig. 15a-o). 
An eGFP or DsRed tag to the C-terminus of this protein did not affect its subcellular 
distribution (Supplementary Fig. 15a-o).
To characterize the vesicle structures labeled by TMEM230, we tested several subcellular 
organelle markers. TMEM230 did not show apparent co-localization with markers for 
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mitochondria, lysosomes or endoplasmic reticulum (Supplementary Fig. 16a-l). The 
perinuclear clusters labeled by TMEM230 were in close proximity to the Golgi apparatus, 
but were distinct from GOLGA2, a marker for the cis-Golgi matrix protein (Supplementary 
Fig. 16m-p’). We then tested syntaxin 6 (STX6), a transmembrane protein predominantly 
enriched in the trans-Golgi network (TGN). We found that STX6 co-localized with 
TMEM230 in these perinuclear clusters and some vesicles (Supplementary Fig. 16q-t), 
suggesting that the perinuclear structures labeled by TMEM230 represent TGN, and 
possibly secretory budding and recycling vesicles.
To test whether these secretory vesicles evolve into synaptic vesicles that are the most 
abundant secretory/recycling vesicles in neurons, we examined synaptophysin (SYP), 
vesicle-associated membrane protein 2 (VAMP2) and vesicular monoamine transporter 2 
(VMAT2), three known transmembrane proteins of synaptic vesicles. We observed co-
localization of TMEM230 and these synaptic vesicle markers (Supplementary Fig. 17a-l, 
and data not shown). The PD-linked mutations did not alter the localization pattern of the 
protein (Supplementary Fig. 17i-l, and data not shown). We confirmed the co-localization of 
TMEM230 with mouse endogenous Syp and Vmat2 in mouse embryonic primary neurons, 
including dopaminergic neurons (Fig. 2a-h). The mouse endogenous Tmem230 was also 
shown to co-localize to the vesicles with endogenous Syp and Vmat2 in the non-transfected 
mouse primary neurons (Fig. 2i-p). Immunoblot data from synaptosome fractionation 
revealed that Tmem230 had an enrichment pattern similar to Syp (Fig. 2q), and immunogold 
electron microscopy indicated that this protein is located in the synaptic vesicle pool region 
in the presynapse (Fig. 2r). These data, therefore, indicate that the TMEM230 is primarily a 
transmembrane protein of synaptic vesicles in neurons.
TMEM230 in recycling endosomes
Synaptic vesicles are continuously recycled through endocytic mechanism following 
exocytosis in order to replenish the reserve vesicle pool28. RAB GTPases and other signal 
proteins coordinate the sorting, trafficking and recycling of these vesicles. Most early 
endocytic steps rely on RAB5A, which mediates fusion of endocytic vesicles to form the 
early endosomes29. To test if TMEM230 is present in early endosomes, we co-transfected 
cells with TMEM230 and RAB5A constructs, and found that TMEM230 and RAB5A co-
localized together in early endosomes (Supplementary Fig. 18a-d).
Early endosomes have three distinct destinations, depending on the sorting signals on the 
early endosomes: degradation in the lysosomes, recycling to the plasma membrane or 
retrieval to the Golgi apparatus. We tested several representative RAB and other proteins. 
We found that the TMEM230 signals partially and weakly co-localized with RAB7 
(Supplementary Fig. 18e-h), a protein that contributes to the biogenesis of late endosomes 
and autophagosomes, and subsequent trafficking to lysosomes. Similarly, the TMEM230 
signals also partially and weakly co-localized with MAP1LC3A (Supplementary Fig. 18i-l), 
an autophagosome marker. We observed that majority of the RAB11A-labeled vesicles were 
consistently TMEM230-positive (Supplementary Fig. 18m-p), suggesting that a major 
fraction of the TMEM230-labeled synaptic vesicles evolves into recycling endosomes, 
leading to the direct reuse of the synaptic vesicles as expected.
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Endosome retrieval to the TGN is mediated by retromer complex. VPS35 is a component of 
the retromer. A D620N mutation in VPS35 has been previously reported in several 
autosomal dominant PD families10,11. To test whether TMEM230 is involved in the vesicles 
retrieval to TGN by retromers, we transfected Neuro-2a cells with both TMEM230 and 
VPS35 constructs, and we observed a remarkable fraction of the TMEM230 signals 
overlapped with VPS35 signals (Fig. 3a-d). We further confirmed this finding using primary 
neurons (Fig. 3e-p). TMEM230 and VPS35 have distinct physiological localizations, with 
TMEM230 to synaptic vesicles, and VPS35 to retromers. The convergence of these two PD-
linked proteins in the endosomal trafficking to TGN pathway suggests that the PD caused by 
mutant VPS35 and TMEM230 may share a common pathogenic pathway that is related to 
defects in synaptic vesicle trafficking and recycling.
TMEM230 in Lewy bodies
Lewy bodies and Lewy neurites in surviving neurons of the affected brain regions are 
pathological hallmarks of idiopathic PD, autosomal dominant PD and dementia with Lewy 
body (DLB), suggesting a shared pathogenic pathway30. SNCA, a dominant PD-linked 
protein, is a major component of the Lewy bodies and Lewy neurites31. We tested whether 
TMEM230 is also involved in the formation of the Lewy bodies and Lewy neurites. We 
analyzed midbrain and neocortex sections from 10 sporadic PD cases and 7 DLB cases, 
respectively. We found that SNCA-positive Lewy bodies and Lewy neurites in these 17 cases 
were also consistently TMEM230-positive, suggesting that TMEM230 is a constitutive 
component of Lewy bodies and Lewy neurites (Supplementary Fig. 19).
Impairment of synaptic vesicle trafficking by mutations
Synaptic vesicle transmembrane proteins are of two obligatory classes: (I) transport proteins 
that are involved in the uptake of neurotransmitters and other components into synaptic 
vesicles; and (II) trafficking proteins that mediate the intracellular traffic of synaptic 
vesicles. The transport proteins of synaptic vesicles are generally large transmembrane 
proteins with 8-12 transmembrane segments. The much smaller molecular size and fewer 
transmembrane segments of TMEM230 compared to the known neurotransmitter transport 
proteins indicate that TMEM230 is likely to be a trafficking protein, rather than a 
neurotransmitter-transport protein of the synaptic vesicles. In the transfected primary 
neurons, the movement of the synaptic vesicles could be readily observed with live imaging 
microscopy. The dispersive pattern of this movement in the soma may be related to vesicle 
trafficking to their functional destinations32,33. We analyzed the synaptic vesicle movement 
by live imaging approach and found that all four PD-linked mutants led to significantly 
slower movement of the synaptic vesicles, as shown by reduced transport speed, track length 
and displacement length when compared to wild-type (Fig. 4).
Increased expression of SNCA by duplication and triplication has been shown to cause 
PD34-36. Our observations of the co-localization of SNCA and TMEM230 in some vesicles 
and vesicle clusters in the PD autopsy samples, together with the vesicle trafficking 
impairment by mutant TMEM230 raise the possibility that mutant TMEM230 may lead to 
impaired SNCA degradation and therefore, increased SNCA levels in cells. We explored this 
possibility in cellular models. Indeed, mild to moderate, but consistent increases in the 
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SNCA level were observed in cells expressing the mutants when compared to those 
expressing the wild-type (Supplementary Fig. 20).
DISCUSSION
We report here a fully co-segregating mutation in TMEM230 in one of the largest families 
with autosomal-dominant, clinically typical and Lewy body confirmed PD. A variant 
Asn855Ser in DNAJC13 was recently reported in this family37. But this variant did not fully 
co-segregate with the disease, as shown by the absence of this variant in three affected 
individuals (II-1, III-1 and III-23)37. Moreover, this variant was present in the unaffected 
individual (II-9), who had not developed any signs of PD when she died at the age of 87 
years. The inconsistency of the phenotype-genotype correlation in multiple individuals 
raised the concern that the variant Asn855Ser in DNAJC13 might not be the disease-causing 
mutation in this family, as the authors also noted37. We performed linkage analysis and 
established a new PD locus to 20pter-p12 using this family. Our whole-exome sequencing 
complemented with Sanger sequencing covered all the known transcripts in the MCR, and 
revealed the c.422G>T (p.Arg141Leu) mutation in TMEM230 to be the only missense 
mutation that fully co-segregates with the disease in the entire family. Moreover, we also 
found a highly prevalent TMEM230 mutation, X184ProGly, in nine PD patients from seven 
Chinese families. These data provide compelling genetic evidence that TMEM230 is the 
new PD-causing gene on the chromosome 20p locus. These data also indicate that although 
the disease modifying effect by the DNAJC13-Asn855Ser could not be excluded37, it is not 
the PD-causing mutation in this large PD family.
Among autopsy samples from four deceased patients (II-1, II-4, II-6 and II-14) in second 
generation, three had confirmed Lewy body pathology. The patient II-1 had all cardinal 
symptoms of PD, with a moderate response to levodopa. In addition, this patient had other 
clinical signs, including pseudo bulbar affect, dysphagia and dementia. Pathological analysis 
of autopsy sample from this patient revealed progressive supranuclear palsy (PSP) 
pathology. But his son (III-1) developed typical PD symptoms at the age of 49 years, with 
good response to levodopa. It remains to be further investigated why the same TMEM230-
Arg141Leu mutation leads to PSP in one case, but PD in the others in this family. However, 
this phenotypic heterogeneity may not be an exception, because some patients with the 
Arg1441Cys or Arg1441His mutation in LRRK2, two well-established PD-causing 
mutations, have also been shown to present with clinical and pathological features of 
PSP7,38,39. These data may suggest an etiological link between PD and PSP.
PD and other parkinsonian disorders are typically sporadic, but disease-causing mutations in 
several genes have been identified in monogenically inherited forms. Among these genes, 
TMEM230 appears to be the only gene that encodes a transmembrane protein of the 
synaptic vesicles. Synaptic vesicles are the most abundant secretory/recycling vesicles in 
neurons. The precise functions of TMEM230, and pathogenic mechanism of the TMEM230-
mediated PD remain to be further elucidated. Based on its molecular features, and its 
relationship with synaptic vesicle and endosomal markers tested in this study, we propose 
that TMEM230 is a trafficking protein of secretory/recycling vesicles, primarily involved in 
exocytosis, endocytosis and recycling of the synaptic vesicles in neurons; and dysfunction of 
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the synaptic vesicles, such as impaired trafficking and recycling, underlies the pathogenesis 
of the TMEM230-linked PD.
Based on the nomenclature proposed by Langston et al1, TMEM230 appears to be the third 
disease-causing gene linked to clinically typical and Lewy body confirmed PD after SNCA 
and LRRK21. VPS35 is linked to autosomal dominant dopa-responsive parkinsonism. 
However, limited brain tissue analysis failed to reveal Lewy body pathology, thus did not 
allow definitive conclusions for Lewy body disease10,40. Our data suggest that TMEM230 
and VSP35 may share a functional pathway in synaptic vesicle/endosome retrograde 
trafficking. Interestingly, LRRK2 may also be involved in vesicle trafficking processes. A 
recent study has shown that LRRK2 phosphorylates a subset of Rabs, which play important 
roles in intracellular vesicle trafficking; and PD-linked LRRK2 mutations increase the 
phosphorylation of these Rabs and inhibit their activity, which may disturb intracellular 
vesicle trafficking41. Thus, the defects of synaptic vesicle/endosome trafficking may be a 
convergent pathway in the pathogenesis of PD. Our findings also imply that improvement of 
the synaptic vesicle/endosome trafficking may have therapeutic effect. Indeed, NAB2, a 
small molecule that promotes endosomal trafficking, has recently been shown to be able to 
reverse PD-related pathological phenotypes in PD patient-derived neurons with a SNCA-
A53T mutation42,43.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Mutations of TMEM230 in patients with PD. (a) Evolutionary conservation of mutated 
amino acids in the TMEM230 protein in different species. Amino acids identical to human 
TMEM230 are in black letters, and non-identical ones are denoted in red letters. The 
mutated amino acids are indicated by arrowheads on the top. (b) Predicted putative 
secondary and tertiary structures. The predominant isoform 2 of TMEM230 is shown. Image 
is colored by rainbow from N (blue) → C (red) terminus. Two major alpha helix regions are 
shown on the left. Mutation sites are indicated by arrows. (c) Schematic diagram showing 
the topology of the TMEM230 protein. Two transmembrane segments (aa 109-129, and aa 
142-162) are shown in blue, with the N- and the C-terminal regions exposed to the cytosol. 
Mutations are indicated by arrows. The X184W and X184PG mutations lead to the C-
terminal addition of six and seven amino acids, respectively, with the last five amino acids 
being identical (HPPHS, blue).
Deng et al. Page 13
Nat Genet. Author manuscript; available in PMC 2018 July 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Localization of TMEM230 to synaptic vesicles in neurons. (a-p) Confocal microscopy was 
performed using transfected (a-h) and non-transfected (i-p) primary neurons from the mouse 
midbrain. Mouse endogenous (endo-) Tmem230, Syn and Vmat2 were detected with 
respective antibodies. Representative co-localization signals are indicated by arrows. (e-h) A 
TMEM230 transfected primary neuron (arrow) shows TMEM230 co-localization with 
endogenous Vmat2 (dopaminergic neuron); the other transfected neuron (arrowhead) that is 
TMEM230-positive, but vmat2-negative, suggesting a non-dopaminergic neuron. (m-p) A 
mouse endogenous Tmem230-positive, but Vmat2-negative (non-dopaminergic neuron) is 
indicated by an arrowhead. (q) Enrichment of Tmem230 in synaptosomes and synaptic 
vesicles. Western blot was performed using four fractions isolated from rat brains as 
indicated. Tmem230 shows a similar enrichment pattern to synaptophysin. (r) Localization 
of Tmem230 in the presynaptic vesicle pool region. Immunogold electron microscopy was 
performed using rat brain sections. A representative perforated synapse in rat CA1 region is 
shown in the center of the image. Presynaptic axonal terminal (Ax) and dendritic spine head 
(Dsh) are shown. Tmem230-positive gold particles are indicated by an arrow. The 
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presynaptic vesicle pool region and postsynaptic density are indicated by black and green 
arrowheads, respectively.
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Figure 3. 
Convergence of TMEM230 and VPS35 in vesicle trafficking/recycling to TGN. (a-d) 
Confocal microscopy was performed using Neuro-2a cells transfected with TMEM230-
eGFP construct together with VPS35-myc as indicated. (e-p) Confocal microscopy was 
performed using mouse primary neurons transfected with TMEM230-eGFP. The mouse 
endogenous Vps35 was detected with an antibody. Representative images showing the 
overlap of the signals (arrows) of TMEM230 and mouse endogenous Vps35. (e-h) A less 
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TMEM230 transfected neuron showing Vps35, but only marginal TMEM230-eGFP is 
indicated by an arrowhead.
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Figure 4. 
Impairment of synaptic vesicle trafficking by PD-linked mutant TMEM230. (a) Fluorescent 
image of synaptic vesicles in transfected primary neurons. Cultured mouse midbrain primary 
neurons were co-transfected with the GFP-tagged VAMP2 expressing vector (pEGFP-
VAMP2) and each of the TMEM230 tag-free constructs in the pIRES2-ZsGreen1 vector. 
The pEGFP-VAMP2 was used to label the synaptic vesicles (Supplementary information). 
White arrowheads mark representative GFP-VAMP2-labeled vesicles quantified in panels b-
e. (b) Movement track of the GFP-VAMP2-labeled vesicles. The trafficking of the vesicles 
in live primary neurons is monitored by confocal microscope and quantified using the Imaris 
software package. The movement tracks of eight representative vesicles from time-lapse live 
confocal images (30 frames with 5-second intervals) are shown, with pseudocolored 
movement tracks marking the position of vesicles at different time points during the 150 
seconds. Images shown in panels (a) and (b) are taken at the time point marked on the 
pseudocolored time scale. (c-e) Quantification of the mean transport speed, track length and 
displacement length of GFP-VAMP2-labeled vesicles. Vesicles in neurons expressing PD-
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linked mutants (TMEM230-Y92C, TMEM230-R141L, TMEM230-X184W and TMEM230-
X184PG) show impaired movement, as measured by transport speed (c), track length (d) and 
displacement length (e), when compared to the wild-type (TMEM230-WT). Data are from 
four independent experiments (1055 moving vesicles in 27 neurons). ** p < 0.01 (Oneway 
ANOVA test). Error bars, mean ± s.e.m.
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